(VIANEWS) – The NASDAQ opens in less than two hours and Arcturus Therapeutics‘s pre-market value is already 4.85% down.
Arcturus Therapeutics’s last close was $31.53, 16.48% under its 52-week high of $37.75.
The last session, NASDAQ ended with Arcturus Therapeutics (ARCT) dropping 4.37% to $31.53. NASDAQ slid 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $3.76.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 8.39. Meaning, the purchaser of the share is investing $8.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.66%.
Yearly Top and Bottom Value
Arcturus Therapeutics’s stock is valued at $31.53 at 08:30 EST, way under its 52-week high of $37.75 and way above its 52-week low of $14.21.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 121.4% and a negative 154.5%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 237.6%, now sitting on 296.24M for the twelve trailing months.
More news about Arcturus Therapeutics (ARCT).
